Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Advanced/Recurrent Lung Cancer or Mesothelioma

NCT01898156 is registered in ClinicalTrials.gov with Kyowa Kirin Korea Co., Ltd. as lead sponsor.

NCT NCT01898156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01898156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Advanced/Recurrent Lung Cancer or Mesothelioma
Lead sponsor
Kyowa Kirin Korea Co., Ltd.
Phase
Phase 1/2
Overall status
Terminated
Start date
July 31, 2013
Completion date
June 30, 2016
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

phase 1 portion : non small cell lung cancer(nsclc), small cell lung cancer(sclc), mesothelioma, phase 2 portion : small cell lung cancer(sclc)